Holen Sie sich die Stockscreener-App
1.36
28.30%
0.30
Vorhandelsmarkt:
1.35
-0.01
-0.74%
Schlusskurs vom Vortag:
$1.06
Offen:
$1.07
24-Stunden-Volumen:
3.80M
Relative Volume:
5.16
Marktkapitalisierung:
$75.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.50M
KGV:
-1.8189
EPS:
-0.7477
Netto-Cashflow:
$-27.75M
1W Leistung:
+37.37%
1M Leistung:
+115.53%
6M Leistung:
+39.19%
1J Leistung:
+22.52%
1-Tages-Spanne:
$1.03
$1.395
1-Wochen-Bereich:
$0.9507
$1.395
52-Wochen-Spanne:
$0.5068
$1.915
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.36 | 59.16M | 0 | -34.50M | -27.75M | -0.7477 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
PDSB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15.00 - GuruFocus
PDSB: Positive Data from Phase 2 Trial of PDS01ADC Published - GuruFocus
Why Is PDS Biotechnology Stock Gaining Wednesday?PDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotech reports 78% response rate in colorectal cancer trial - Investing.com
PDS Biotech reports 78% response rate in colorectal cancer trial By Investing.com - Investing.com South Africa
Interim PDS01ADC data lift responses in tough mCRC for PDS Biotech (PDSB) - Stock Titan
PDS Biotech Announces Publication of Positive PDS01ADC - GlobeNewswire
Aug Drivers: Is PDS Biotechnology Corporation trading at a discount2026 Earnings Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - AlphaStreet
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - marketscreener.com
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and - GlobeNewswire
PDS Biotechnology FY 2025 earnings preview - MSN
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - Bitget
Published on: 2026-03-28 11:50:07 - baoquankhu1.vn
Aug Breakouts: Whats the analyst consensus on PDS Biotechnology CorporationMarket Trend Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
PDS Biotechnology to announce Q4 and full year results on March 30 with clinical and corporate update - Traders Union
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - The Manila Times
PDS Biotech pairs 2025 results with a clinical update on March 30 - Stock Titan
PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday - Defense World
Will PDS Biotechnology Corporation stock go up in YEARPortfolio Profit Report & Safe Entry Momentum Tips - baoquankhu1.vn
Block Trades: Can PDS Biotechnology Corporation stock outperform in a bear market2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
PDSB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PDS Biotechnology (PDSB) CEO receives 548,782-share stock option award - Stock Titan
[Form 4] PDS Biotechnology Corp Insider Trading Activity - Stock Titan
PDS Biotechnology (PDSB) awards 150,000 stock options to Chief Scientific Officer - Stock Titan
PDS Biotechnology (PDSB) CMO receives grant of 300,000 stock options - Stock Titan
PDS Biotechnology grants 300,000 options to executive | PDSB SEC FilingForm 4 - Stock Titan
PDS Biotechnology (PDSB) director Ilian Iliev receives grant of 54,876 stock options - Stock Titan
PDS Biotechnology director granted 54,876 options | PDSB SEC FilingForm 4 - Stock Titan
Director option grant at PDS Biotechnology (PDSB) totals 54,876 options - Stock Titan
PDS Biotechnology (PDSB) director awarded 54,876 stock options in new grant - Stock Titan
PDS Biotechnology receives Nasdaq notice for minimum bid price deficiency - Investing.com Australia
Nasdaq warns PDS Biotechnology (NASDAQ: PDSB) on $1.00 bid price rule - Stock Titan
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB) - The Wall Street Transcript
PDS Biotech Announces Amended Protocol for Phase 3 Trial - National Today
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):